• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New Sequencing Method Detects Cancer DNA in Blood

by
November 9, 2026
in Health
Reading Time: 6 mins read
0
New Sequencing Method Detects Cancer DNA in Blood

New Sequencing Method Detects Cancer DNA in Blood

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers have developed a novel sequencing technique called Methyltransferase-Assisted Single Duplex sequencing, or MASD-seq, which significantly improves the accuracy of detecting circulating tumor DNA in blood samples. Published in EMBO Molecular Medicine, the study introduces a method that physically links the two strands of DNA to enable error correction within a single read pair. This approach addresses a longstanding limitation in cancer diagnostics, where high sequencing error rates often obscure the low levels of tumor DNA present in the bloodstream. By leveraging enzymatic methylation and specific restriction enzyme digestion, the team achieved error rates as low as 5.4 × 10−7 for certain mutation types, a level of precision that allows for the detection of subtle mutational burdens in healthy blood.

The core innovation of MASD-seq lies in its ability to preserve genetic information from both strands of the original DNA molecule. Traditional duplex sequencing methods often struggle with the low efficiency of recovering paired DNA strands after they separate during library preparation. MASD-seq overcomes this by using hairpin adapters to covalently link the Watson and Crick strands throughout the workflow. This physical linkage allows the method to identify consensus sequences from a single read pair, thereby improving the efficiency of double-strand consensus recovery by more than one order of magnitude compared to standard approaches that require multiple reads to reconstruct the original duplex.

To ensure high accuracy, the method employs the CpG methyltransferase M.SssI to methylate CpG sites before enzymatic conversion. This step protects specific cytosine bases from being converted to uracil, which would otherwise lose the original strand information. By blocking this conversion, MASD-seq enables the correction of CpG>TpG mutations, a type prevalent in human cancers including colorectal cancer. The team also utilized MspI digestion to enrich for tumor-derived mutations. This restriction enzyme recognizes specific DNA sequences and helps reduce genome complexity, effectively targeting regions where tumor mutations are most likely to be found.

In technical validation experiments using GM12878 and HEK293T cell lines, MASD-seq demonstrated exceptional precision. The method achieved an overall CpG>TpG error rate of 5.4 × 10−7 and an average transversion error rate of 4.1 × 10−8. These low error rates allowed the researchers to detect age-associated mutational burdens in plasma cell-free DNA from nine healthy volunteers. The study revealed a clear positive correlation between age and mutation burden for correctable mutation types, indicating that the method is sensitive enough to distinguish physiological changes from background noise.

The team further investigated the feasibility of using a reduced representation sequencing assay, termed MspI-RRS, to profile tumor tissue mutations. By analyzing whole-genome sequencing data from the U-CAN cohort, which included 840 microsatellite stable and 223 microsatellite instability colorectal cancer samples, they found that the MspI-targeted region was enriched for CpG>TpG mutations. Specifically, the mutation burden in this region was 4.1-fold higher in microsatellite instability tumors and 3.0-fold higher in microsatellite stable tumors compared to the whole genome. This enrichment suggests that MspI-RRS can serve as a cost-efficient strategy for identifying tumor-specific mutations without the need for comprehensive whole-genome sequencing.

When applied to 31 colorectal cancer tissue samples, the MspI-RRS assay identified a median of 4,817 mutations in high microsatellite instability patients and 579 in microsatellite stable patients. The assay showed a strong correlation with whole-exome sequencing results, with a Spearman’s correlation coefficient of 0.79. Furthermore, the tumor mutation burden detected by MspI-RRS demonstrated an area under the curve of 0.995 for predicting immunotherapy candidates. This high predictive accuracy underscores the potential of the method to identify patients who may benefit from immune-checkpoint inhibitors, a critical consideration in modern oncology treatment plans.

In a preliminary clinical validation study, the researchers applied MASD-seq to preoperative plasma samples from 17 colorectal cancer patients. The assay successfully identified tumor-derived mutations in 16 of the 17 cases, achieving a detection rate of 94.1%. The method distinguished cancer patients from healthy controls with an area under the curve of 0.970. Using a mutation count cutoff of two or more, the assay achieved 100% specificity in healthy controls, while maintaining a sensitivity of 91.7% in high microsatellite instability patients. These results indicate that MASD-seq can reliably detect circulating tumor DNA in a clinical setting, providing a non-invasive tool for monitoring disease status.

The study also examined the performance of MASD-seq in postoperative samples from eight high microsatellite instability patients. Notably, the circulating tumor DNA signals detected in all preoperative samples were no longer detectable after surgery. The tumor fraction in blood declined to undetectable levels in all cases, validating the high specificity of the method. Over a median follow-up period of 24 months, none of the patients with undetectable postoperative ctDNA experienced clinical recurrence. This finding suggests that the method could be valuable for monitoring minimal residual disease and predicting the risk of relapse in patients undergoing curative-intent surgery.

The researchers compared MASD-seq with a commercial hybrid-capture-based targeted sequencing assay that supports both single-strand and double-strand consensus analysis. In a spike-in experiment, MASD-seq and double-strand consensus analysis showed substantially lower backgrounds than single-strand consensus, with MASD-seq achieving a background of 3.6 × 10−6. Despite its high sensitivity, the commercial double-strand consensus method had a relatively low recovery rate, detecting fewer mutant alleles at low fractions. In contrast, MASD-seq detected a higher number of mutant alleles, resulting in markedly higher signal-to-noise ratios. This superior performance highlights the analytical advantage of the single-duplex approach in detecting ultra-low abundance mutations.

Despite its promising results, the study acknowledges several limitations. The current experimental validation supports the clinical applicability of MASD-seq primarily in colorectal cancer, while its applicability to other tumor types remains to be validated. The method is less suitable for tumors with low CpG>TpG burdens or high uncorrectable mutation rates, such as liver cancer and melanoma. Additionally, the analytical advantages demonstrated in the study were derived from controlled spike-in models and reference materials rather than exclusively from clinical patient-derived samples. Further research is needed to optimize library construction and bioinformatics pipelines to enhance molecule recovery and reduce background error rates.

By combining high-accuracy sequencing with cost-efficient mutation profiling, the method offers a robust tool for detecting circulating tumor DNA. The ability to distinguish cancer patients from healthy controls with high accuracy, along with the potential to monitor treatment response, positions MASD-seq as a candidate for future clinical applications.

The work was published in EMBO Molecular Medicine in August 2026. The research focuses on the technical challenge of recovering double-strand consensus sequences in standard duplex sequencing, where the efficiency of pairing complementary strands after library preparation is often low. Previous methods, such as circle sequencing and CODEC, have attempted to address this by physically linking DNA fragments, but they typically rely on single-strand information or suffer from suboptimal molecular capture efficiency. MASD-seq distinguishes itself by preserving genetic information from both strands of the original DNA molecule, aiming to achieve true single-duplex sequencing on next-generation sequencing platforms.

A key technical aspect of the method involves the use of a double CpG correction algorithm to enhance accuracy. This algorithm leverages information from two complementary methylated CpG sites to confirm genuine mutations. In a true CpG>TpG mutation, the CpG dinucleotide is lost on both strands, whereas errors from incomplete enzymatic conversion or hemi-methylation affect only one strand. By requiring both a T:A pair and the corresponding conversion on the opposite strand, the algorithm reduced the CpG>TpG error rate by approximately 50% in cell line validations. This refinement is critical for distinguishing true somatic variants from sequencing artifacts, particularly in the context of low-abundance tumor DNA.

The clinical validation included a detailed analysis of fragment length and its impact on detection sensitivity. The study found that shorter cell-free DNA fragments, specifically those under 100 base pairs, showed greater mutation enrichment compared to longer fragments exceeding 135 base pairs. The assay demonstrated that this fragment-based enrichment improved both single nucleotide variant detection and tumor fraction estimation, providing a nuanced layer of sensitivity for the clinical application of the method.

Cost efficiency is another significant advantage of the MspI-RRS approach for tissue profiling. The study notes that using MspI-RRS requires approximately 40 Gb of sequencing data per patient case to achieve a depth of about 50x, whereas whole-genome sequencing requires 200 Gb per case to reach a depth of about 30x. This represents a more than five-fold improvement in cost efficiency, making it a feasible strategy for profiling mutations in microsatellite instability-high tumor samples where comprehensive driver gene information may not be strictly necessary for initial treatment decisions.

Subject of Research: Methyltransferase-assisted single duplex sequencing for detecting circulating tumor DNA

Article Title: Methyltransferase-assisted single duplex sequencing for detecting circulating tumor DNA

Article References: Jiang, Z., Wu, Y., Guo, Y., Luo, R., Wang, W., Tang, F., Fu, W., Zhou, X., & Wen, L. (2026). Methyltransferase-assisted single duplex sequencing for detecting circulating tumor DNA. EMBO Molecular Medicine, 18(10), 3961-3978. https://doi.org/10.1038/s44321-026-00509-2

Image Credits: AI Generated

DOI: 10.1038/s44321-026-00509-2

Keywords: Methyltransferase-assisted, single, duplex, sequencing, detecting, circulating, tumor, scientific research

News Source: Nathaniel Bowman. (November 9, 2026). New Sequencing Method Detects Cancer DNA in Blood. Scienmag.

Tags: CirculatingdetectingduplexMethyltransferase-assistedscientific researchsequencingsingletümör
Share12Tweet7Share2ShareShareShare1

Related Posts

Canadian AMR Surveillance Program Shows Moderate One Health Integration in Evaluation

Canadian AMR Surveillance Program Shows Moderate One Health Integration in Evaluation

November 17, 2026
Systematic Review Details Complex Ethical Challenges Across Head and Neck Oncology Trajectories

Systematic Review Details Complex Ethical Challenges Across Head and Neck Oncology Trajectories

November 17, 2026

Study Estimates Total US Neuromyelitis Optica Economic Burden at 1.06 Billion Dollars

November 17, 2026

Postoperative Anaesthesia Video Visits Proved Feasible in Outpatient Pilot Study

November 17, 2026

POPULAR NEWS

  • Alloplastic Temporomandibular Joint Replacement Offers Uncertain Benefits After Mandibular Neoplasm Resection

    Alloplastic Temporomandibular Joint Replacement Offers Uncertain Benefits After Mandibular Neoplasm Resection

    29 shares
    Share 12 Tweet 7
  • Serum Mass Spectrometry Predicts Treatment Response in HER2-Positive Breast Cancer

    29 shares
    Share 12 Tweet 7
  • Polypharmacy Linked to Higher Odds of Sarcopenia in Older Adults

    29 shares
    Share 12 Tweet 7
  • Adapted Virtual Presence Tool Proves Feasible in Pilot Manikin Simulation Courses

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Review Evaluates GLP-1 Receptor Agonists as Host-Directed Adjuncts in Infectious Diseases

Canadian AMR Surveillance Program Shows Moderate One Health Integration in Evaluation

Systematic Review Details Complex Ethical Challenges Across Head and Neck Oncology Trajectories

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.